Showing 47 results
-
Media Release /Novartis Canada applauds the positive funding recommendations for Scemblix® (asciminib) for both newly diagnosed and previously treated patients with Philadelphia chromosome-positive chronic myeloid…
-
Media Release /Novartis applauds Ontario’s bold leadership in launching the FAST program, which accelerates access to breakthrough therapies like Scemblix® for patients living with cancer.Scemblix® (asciminib) was…
-
Media Release /Quebec has the highest rate of breast cancer in Canada.1 The Government of Quebec recently endorsed lowering the breast cancer screening age for women,2,3 reflecting the province’s commitment…
-
Media Release /The Novartis Health Equity Initiative continues to support projects tackling systemic health disparities and promoting equitable access to healthcare across Canada.To date, the initiative drew over…
-
Media Release /MONTREAL, QC, November 25, 2025 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the appointment of Dimitri Gitas as Country…
-
Media Release /Eligible Canadian patients with heterozygous familial hypercholesterolemia (HeFH) are one step closer to publicly funded access to cholesterol lowering treatment.Montréal, Québec, August 21, 2025 –…
-
Media Release /• Scemblix® is first to show superior efficacy and a favourable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies.1,2• …
-
Media Release /• Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS)• …
-
Media Release /Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancerMomentum builds…
-
Media Release /Despite endocrine therapy (ET), the risk of recurrence for people diagnosed with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (eBC…
